CSIMarket
 


Longeveron Inc   (LGVN)
Other Ticker:  
 
 

LGVN's Revenue Growth by Quarter and Year

Longeveron Inc 's Revenue results by quarter and year




LGVN Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.15 -0.72 0.00
III Quarter September 0.15 0.27 0.23 0.00
II Quarter June 0.22 0.47 0.49 0.00
I Quarter March 0.28 0.37 0.00 0.00
FY   0.65 1.26 0.00 0.00



LGVN Revenue third quarter 2023 Y/Y Growth Comment
Longeveron Inc reported fall in Revenue in the third quarter 2023 by -44.44% to $ 0.15 millions, from the same quarter in 2022.
The drop in the third quarter 2023 Longeveron Inc 's Revenue compares unfavorably to the Company's average Revenue decline of -22.38%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 197 other companies have achieved higher Revenue growth. While Longeveron Inc ' s Revenue drop of -44.44% ranks overall at the positon no. 3487 in the third quarter 2023.




LGVN Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -44.44 % 17.39 % - -
II Quarter June -53.19 % -4.08 % - -
I Quarter March -24.32 % - - -
FY   - - - -

Financial Statements
Longeveron Inc 's third quarter 2023 Revenue $ 0.15 millions LGVN's Income Statement
Longeveron Inc 's third quarter 2022 Revenue $ 0.27 millions Quarterly LGVN's Income Statement
New: More LGVN's historic Revenue Growth >>


LGVN Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -44.44 % - -
III Quarter September -31.82 % -42.55 % -53.06 % -
II Quarter June -21.43 % 27.03 % - -
I Quarter March 86.67 % - - -
FY (Year on Year)   - - - -




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #198
Healthcare Sector #523
Overall #3487

Revenue Y/Y Growth Statistics
High Average Low
14.22 % -22.38 % -53.43 %
(Sep 30 2022)   (Jun 30 2023)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #198
Healthcare Sector #523
Overall #3487
Revenue Y/Y Growth Statistics
High Average Low
14.22 % -22.38 % -53.43 %
(Sep 30 2022)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Longeveron Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
81.17 % -11.94 % -52.56 %
(Mar 31 2023)  


LGVN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Longeveron Inc reported fall in Revenue from the second quarter by -31.82% to $ 0.15 millions, from $ 0.22 millions released in the previous quarter.

But that's not big problem, as Longeveron Inc 's Revenue generally gravitate to plunge in this quarter Matumbina Neves, an industry veteran noted.

Within Major Pharmaceutical Preparations industry 139 other companies have achieved higher Revenue quarter on quarter growth. While Longeveron Inc 's Revenue growth quarter on quarter, overall rank is 2672.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #140
Healthcare Sector #386
Overall #2672
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #140
Healthcare Sector #386
Overall #2672
Revenue Q/Q Growth Statistics
High Average Low
81.17 % -11.94 % -52.56 %
(Mar 31 2023)  


LGVN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Longeveron Inc reported fall in Revenue sequentially by -31.82% to $ 0.15 millions, from $ 0.22 millions released in the previous quarter.

This is not important concern, as Revenue generally seem to dip in the III. Quarter.

Within Major Pharmaceutical Preparations industry 139 other companies have achieved higher Revenue quarter on quarter growth. While Longeveron Inc 's Revenue growth quarter on quarter, overall rank is 2672.


Longeveron Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 0.80 $ 0.92 $ 1.16 $ 1.26 $ 0.38
Y / Y Revenue Growth (TTM) 110.53 % 163.69 % 214.59 % - -
Year on Year Revenue Growth Overall Ranking # 59 # 183 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -12.57 % -21.39 % -7.25 % 230.26 % 9.51 %
Seq. Revenue Growth (TTM) Overall Ranking # 1007 # 3212 # 0 # 2044 # 2620




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2023 period, Longeveron Inc 's cumulative twelve months Revenue were $ 1 millions, company would post below average annual Revenue growth of 9.51% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Longeveron Inc 's Revenue growth from the 0.22% growth in Jun 30 2023.

Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 59, from total ranking in previous quarter at 183.

Revenue TTM Q/Q Growth Statistics
High Average Low
214.59 %
162.94 %
110.53 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 23
Overall # 59

Revenue TTM Y/Y Growth Statistics
High Average Low
214.59 %
162.94 %
110.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 79
Sector # 198
S&P 500 # 1007
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2023 period, Longeveron Inc 's cumulative twelve months Revenue were $ 1 millions, company would post below average annual Revenue growth of 110.53% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Longeveron Inc 's Revenue growth from the 0.22% growth in Jun 30 2023.

Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 59, from total ranking in previous quarter at 183.

Revenue TTM Q/Q Growth Statistics
High Average Low
214.59 %
162.94 %
110.53 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 23
Overall # 59

Revenue TTM Y/Y Growth Statistics
High Average Low
214.59 %
162.94 %
110.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 79
Sector # 198
S&P 500 # 1007




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LGVN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for LGVN's Competitors
Revenue Growth for Longeveron Inc 's Suppliers
Revenue Growth for LGVN's Customers

You may also want to know
LGVN's Annual Growth Rates LGVN's Profitability Ratios LGVN's Asset Turnover Ratio LGVN's Dividend Growth
LGVN's Roe LGVN's Valuation Ratios LGVN's Financial Strength Ratios LGVN's Dividend Payout Ratio
LGVN's Roa LGVN's Inventory Turnover Ratio LGVN's Growth Rates LGVN's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc-0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Bionexus Gene Lab Corp -0.83%$ -0.831 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions
Scientific Industries Inc -3.16%$ -3.165 millions
Akumin Inc -3.21%$ -3.205 millions
Syros Pharmaceuticals Inc -3.32%$ -3.315 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com